The Relationship Between Body Mass Index and Lower Urinary Tract Symptoms in Men

Yıl 2019, Cilt: 5 Sayı: 2, 138 - 144, 28.08.2019

Ali Aslan , Abdullah Çırakoğlu , Yeliz Kaşko Arıcı

https://doi.org/10.19127/mbsjohs.591267

Cited By: 1

Öz

Objective:
The studies evaluating, association between obesity and lower urinary tract symptoms
(LUTS) are limited. Our study’s objective was to determine the correlation
between obesity and LUTS in men.

Methods:
Information of 639 patients who were aged between 37 and 92, had not been
treated for BPH before, had moderate or severe LUTS, had International Prostate
Symptom Score (IPSS) ≥8 and had prostate-specific antigen (PSA) value less than
4 ng/ml was evaluated retrospectively. Measured Body Mass Index (BMI) was
classified in accordance with World Health Organization (WHO).

Results:
A statistically significant difference was present between BMI groups with
respect to post-void residual urine volume (PVR) (p=0.017). PVR level of the
obesity group’s PVR level was found to be significantly lower when compared to
the normal group (p<0.05). In patients with diabetes mellitus (DM), only PVR
parameter among LUTS was found to differ significantly from BMI groups (p=0.037). In
patients with DM, the mean of PVR of obese patients was detected to be
significantly lower when compared to the mean of normal patients (p<0.05).
In patients with cardiovascular disease (CD), only Qmax and Qave parameters
were found to differ significantly from BMI groups. (p=0.001 and p<0.001,
respectively). In patients with CD, the mean Qmax of obese patients was
significantly higher than the average of normal-weight patients (p<0.05).

Conclusion:
Although there is no association between obesity and
LUTS except PVR, we think that the risk of obesity associated with DM and CD
would significantly increase the risk of LUTS.

Anahtar Kelimeler

Lower urinary tract symptoms, Body mass index, Obesity, Urology

Kaynakça

• Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub‐committee of the International Continence Society. Neurourol Urodynam. 2002;21(2):167-78.
• Altunkaynak BZ, Ozbek E. Obesity: Causes And Treatment Alternatives. Van Med J. 2006;13(4):138-42.
• Barqawi AB, Golden BK, O'Donnell C, Brawer MK, Crawford ED. Observed effect of age and body mass index on total and complexed PSA: analysis from a national screening program. Urology. 2005;65(4):708-12.
• Bart S, Ciangura C, Thibault F, Cardot V, Richard F, Basdevant A, et al. Stress urinary incontinence and obesity. Prog Urol. 2008;18(8):493-8.
• Bilge C, Beji NK. Obesity and Lower Urinary Tract Symptoms in Women. Florence Nightingale J Nurs. 2016;24(2):72-9.
• Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol. 2006;49(4):651-8.
• Cetinkaya M, Oztekin V. Benign prostatic hyperplasia and heredity. Bull Urooncol. 2011;4:20-2.
• Dahle SE, Chokkalingam AP, Gao YT, Deng J, Stanczyk FZ, Hsing AW. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol. 2002;168(2):599-604.
• Fitzgerald MP, Link CL, Litman HJ, Travison TG, McKinlay JB. Beyond the lower urinary tract: the association of urologic and sexual symptoms with common illnesses. Eur Urol. 2007;52(2):407-15.
• Gann PH, Hennekens CH, Grodstein F, Stampfer MJ, Longcope C, Verhoek‐Oftedahl W. A prospective study of plasma hormone levels, nonhormonal factors, and development of benign prostatic hyperplasia. Prostate. 1995;26(1):40-9.
• Giovannucci E, Rimm EB, Chute CG, Kawachi I, Colditz GA, Stampfer MJ, et al. Obesity and benign prostatic hyperplasia. Am J Epidemiol. 1994;140(11):989-1002.
• Hammarsten J, Högstedt B, Holthuis N, Mellström D. Components of the metabolic syndrome risk factors for the development of benign prostatic hyperplasia. Prostate Cancer P D. 1998;1(3):157.
• Konwar R, Chattopadhyay N, Bid HK. Genetic polymorphism and pathogenesis of benign prostatic hyperplasia. BJU Int. 2008;102(5):536-44.
• Kristal AR, Chi C, Tangen CM, Goodman PJ, Etzioni R, Thompson IM. Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increase. Cancer. 2006;106(2):320-8.
• Ochiai A, Fritsche HA, Babaian RJ. Influence of anthropometric measurements, age, and prostate volume on prostate-specific antigen levels in men with a low risk of prostate cancer. Urology. 2005;66(4):819-23.
• Onat A, Ceyhan K, Başar Ö, Erer B, Toprak S, Sansoy V. Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels a prospective and cross-sectional evaluation. Atherosclerosis. 2002;165(2):285-92.
• Parsons JK. Benign prostatic hyperplasia and male lower urinary tract symptoms: epidemiology and risk factors. Curr Blad Dysfunct Rep. 2010;5(4):212-8.
• Pasquali R, Casimirri F, Cantobelli S, Melchionda N, Morselli Labate AM, Fabbri R, et al. Effect of obesity and body fat distribution on sex hormones and insulin in men. Metabolism. 1991;40(1):101-4.
• Sarma AV, Jaffe CA, Schottenfeld D, Dunn R, Montie JE, Cooney KA, et al. Insulin-like growth factor-1, insulin-like growth factor binding protein-3, and body mass index: clinical correlates of prostate volume among Black men. Urology. 2002;59(3):362-7.
• Signorello LB, Tzonou A, Lagiou P, Samoli E, Zavitsanos X, Trichopoulos D. The epidemiology of benign prostatic hyperplasia: a study in Greece. BJU Int. 1999;84(3):286-91.
• Takeda M, Araki I, Kamiyama M, Takihana Y, Komuro M, Furuya Y. Diagnosis and treatment of voiding symptoms. Urology. 2003;62(5):11-9.
• Yalcin O, editor. Basic Urogynecology. Istanbul: Nobel Medical Publishing; 2009.p.20-22.
• Yüksel A. Nutritional Status of A Morbid Obese Patient After Three Years of Bariatric Surgery: Case Report. İzmir Katip Çelebi Univ Fac Health Sci J. 2016; 1(1): 39-45.